Latest Health News

Little Green Pharma reported a robust 40% revenue increase for FY25, driven by strong European sales and the strategic acquisition of Health House. The company also advanced clinical research and secured new therapy funding, positioning itself for continued growth.

Omni Bridgeway reports robust investment performance for FY25, highlighted by record proceeds and a landmark Fund 9 transaction that strengthens its balance sheet and strategic position.

Pure Hydrogen Corporation has marked significant progress in its clean energy transition, delivering Australia's first hydrogen fuel cell garbage truck and securing multi-million dollar contracts with industry leaders TOLL Transport and Heidelberg Materials.

Farm Pride Foods reports a 15% rise in production following successful repopulation of Avian Influenza-impacted farms, alongside improved cash flow and strategic loan conversion.

RLF AgTech has secured major national distribution agreements in Australia, launched a comprehensive retail rollout, and restructured its manufacturing arm, LiquaForce, to drive growth and operational efficiency. The company also reported strong financial performance and expanded its footprint across Asia.

Adherium Limited reports a surge in US commercial patients for its Hailie Smartinhaler platform, alongside strategic hires and a new product launch compatible with AstraZeneca inhalers, underpinning plans for a capital raise.

Cluey’s Q3 FY25 results reveal a strong 24% surge in new student enrolments and a narrowing underlying EBITDA loss, signaling a pivotal step toward profitability and renewed revenue growth.

Microba Life Sciences reports robust growth in microbiome diagnostic testing across Australia and the UK, while advancing US market entry plans and transitioning its Therapeutics business to a partnering model.

Zoono Group Limited reports strong progress in its shelf-life extension technology trials across multiple continents, with successful UK supermarket trials paving the way for a national roll-out in FY26. Despite a quarterly operating cash outflow, the company expects improved sales and sufficient funding to meet its near-term objectives.

Optiscan Imaging Ltd has revealed its next-generation InForm™ pathology imaging device and strengthened its executive team, while reporting a robust cash position supported by a $1.775 million R&D tax refund for the quarter ended 31 March 2025.

Orthocell has secured Health Canada approval for its nerve repair product Remplir™, adding the US$75 million Canadian market and expanding its total addressable market to US$1.8 billion. The company plans to appoint local distributors and expects first sales in H2 2025.

Actinogen Medical advances its XanaMIA phase 2b/3 Alzheimer’s trial with faster patient enrolment and expands clinical sites, while achieving a pivotal FDA meeting outcome for its depression program. The company maintains a strong cash position, supporting ongoing development and commercialization efforts.